Tasly's Subsidiary Receives Regulatory Approval for Vonoprazan Fumarat Tablets on May 22

GateNews
According to an official announcement on May 22, Tasly Pharmaceutical's wholly-owned subsidiary, Jiangsu Tasly Dieyi Pharmaceutical Co., Ltd., received a drug registration certificate for Vonoprazan Fumarat Tablets from China's National Medical Products Administration. The drug is indicated for reflux esophagitis and is used in combination with appropriate antibiotics to eradicate Helicobacter pylori.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments